Bartosz Wasąg

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 492 citations · Full text

Pkc412 Inhibitor, Imatinib-resistant Mutants, Gastrointestinal Oncology +9

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Surgical Oncology, Bone Sarcoma Group, Gastrointestinal Oncology +8

Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Antonio J. Vallejo‐Vaz, Christophe Stevens, Alexander R.M. Lyons et al. · The Lancet · 2021 · 285 citations · Full text

Family Medicine, Metabolic Syndrome, Lipid Disorder +10

Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity

Maria Dêbiec‐Rychter, Bartosz Wasąg, Michel Stul et al. · The Journal of Pathology · 2004 · 214 citations

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)

Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni et al. · Journal of Thoracic Oncology · 2019 · 147 citations · Full text